Baseline Characteristics
Cross-source consensus on Baseline Characteristics from 1 sources and 4 claims.
1 sources · 4 claims
Other
Other
Other
Highlighted claims
- Three corrections were made to Supplementary Table 2. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
- Supplementary Table 2 documents baseline characteristics of the trial participants. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
- The corrections are intended to improve accurate reporting of baseline disease severity in the benralizumab trial. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
- The baseline characteristics corrections include eosinophil count values and prior biologic therapy percentage. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial